Back to top
more

Boundless Bio, Inc. (BOLD)

(Delayed Data from NSDQ)

$8.59 USD

8.59
56,008

-0.51 (-5.60%)

Updated May 10, 2024 04:00 PM ET

After-Market: $8.56 -0.03 (-0.35%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[BOLD]

Reports for Purchase

Showing records 21 - 40 ( 89 total )

Industry: Medical - Biomedical and Genetics

Record: 21

08/07/2019

Company Report

Pages: 8

AT-132 Registration Strategy Complemented by Progress on Next Value Drivers Mark 1H19

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 22

08/07/2019

Company Report

Pages: 6

Makes a Date for BLA Filing in Mid 2020

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 23

08/07/2019

Daily Note

Pages: 13

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 24

05/08/2019

Company Report

Pages: 7

1Q19 Financials; New Look Neuromuscular Company Looking Good in 2019

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 25

05/08/2019

Company Report

Pages: 8

Big End of Year in Store; Pipeline Pivot to Neuromuscular Diseases Widely Anticipated

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 26

05/02/2019

Daily Note

Pages: 9

Combination of Surrogate and Clinical Endpoints Position AMT132 for a 2020 Approval

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 27

05/02/2019

Daily Note

Pages: 9

Another Impressive MTM Update, Discussions with Regulators up Next in Q3:19

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 28

04/26/2019

Company Report

Pages: 26

Vectorized ASO''s for DMD; a Trip Down Memory Lane; Raising Target to $48

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 29

04/26/2019

Company Report

Pages: 26

Vectorized ASO''s for DMD; a Trip Down Memory Lane; Raising Target to $48

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 30

04/18/2019

Industry Report

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 31

04/09/2019

Company Report

Pages: 9

BOLD Makes Targeted Move into DMD

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 32

04/09/2019

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 33

04/05/2019

Industry Report

Pages: 11

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 34

03/18/2019

Company Report

Pages: 12

Keeping an Eye Out for Pompe and Expansion Into a New Neuromuscular Indication; Raising Target to $44

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 35

02/28/2019

Company Report

Pages: 8

No Fireworks yet; However, 2H19 Looks More Promising

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 36

02/28/2019

Company Report

Pages: 8

FY18 Financials; Important MTM Cohort Two Data Ahead at ASGCT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 37

02/28/2019

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 38

01/31/2019

Daily Note

Pages: 4

As Expected, BOLD to Enroll Additional ASPIRO Patients, Data Update at ASGCT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 39

01/11/2019

Company Report

Pages: 8

AT132 Accelerated Approval During 2020 Is Well Within the Realm of Possibilities

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 40

11/07/2018

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party